Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients

Reviews imlifidase, FcRn inhibitors, anti-IL-6/IL-6R and plasma-cell-directed anti-CD38 agents, and argues the central point that no single agent can control all facets of antibody generation and injury — the future of AbMR treatment is protocols combining multiple agents in a logical sequence to remove pathogenic DSAs and block their re-emergence.